Last updated on November 2018

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes


Brief description of study

This is an open-label Phase IIIb study of dabrafenib in combination with trametinib in the adjuvant treatment of melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm, as well as safety, efficacy and health-related outcomes. ' Approximately 600 subjects will be enrolled to receive dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination therapy for 12 months. At enrollment, subjects will be instructed on the pyrexia management algorithm.

This study consists of two Periods for Enrolled subjects:

  • Treatment Period - subjects will receive up to 12 months of treatment.
  • Follow-up Period - subjects will be followed through 24 months from their first dose date for relapse, and through end of study for overall survival. Follow-up will start once treatment is complete or is prematurely discontinued and continue through the end of the study, regardless of disease recurrence.

Clinical Study Identifier: NCT03551626

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Northwood, United Kingdom
  Connect »

Novartis Investigative Site

Cambridge, United Kingdom
  Connect »

Novartis Investigative Site

Boulogne Billancourt, France
  Connect »

Novartis Investigative Site

Clermont Ferrand cedex 1, France
  Connect »

Novartis Investigative Site

Grenoble Cédex 9, France
  Connect »

Novartis Investigative Site

Marseille Cedex 9, France
  Connect »

Novartis Investigative Site

Inverness, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.